Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys

References

• Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29:Suppl 1 74 - 81; http://dx.doi.org/10.1111/j.1478-3231.2008.01934.x; PMID: 19207969
   PubMed Web of Science ®Google Scholar
• Brown RS. Hepatitis C and liver transplantation. Nature 2005; 436:973 - 8; http://dx.doi.org/10.1038/nature04083; PMID: 16107838
   PubMed Web of Science ®Google Scholar
• Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011; 474:208 - 11; http://dx.doi.org/10.1038/nature10168; PMID: 21654804
   PubMed Web of Science ®Google Scholar
• Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446:801 - 5; http://dx.doi.org/10.1038/nature05654; PMID: 17325668
   PubMed Web of Science ®Google Scholar
• Meredith LW, Wilson GK, Fletcher NF, McKeating JA. Hepatitis C virus entry: beyond receptors. Rev Med Virol 2012; 22:182 - 93; http://dx.doi.org/10.1002/rmv.723; PMID: 22392805
   PubMed Web of Science ®Google Scholar
• Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938 - 41; http://dx.doi.org/10.1126/science.282.5390.938; PMID: 9794763
   PubMed Web of Science ®Google Scholar
• Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21:5017 - 25; http://dx.doi.org/10.1093/emboj/cdf529; PMID: 12356718
   PubMed Web of Science ®Google Scholar
• Kitadokoro K, Bordo D, Galli G, Petracca R, Falugi F, Abrignani S, et al. CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs. EMBO J 2001; 20:12 - 8; http://dx.doi.org/10.1093/emboj/20.1.12; PMID: 11226150
   PubMed Web of Science ®Google Scholar
• Levy S, Nguyen VQ, Andria ML, Takahashi S. Structure and membrane topology of TAPA-1. J Biol Chem 1991; 266:14597 - 602; PMID: 1860863
   PubMed Web of Science ®Google Scholar
• Oren R, Takahashi S, Doss C, Levy R, Levy S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol 1990; 10:4007 - 15; PMID: 1695320
   PubMed Web of Science ®Google Scholar
• Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 1997; 11:428 - 42; PMID: 9194523
   PubMed Web of Science ®Google Scholar
• Yáñez-Mó M, Alfranca A, Cabañas C, Marazuela M, Tejedor R, Ursa MA, et al. Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with alpha3 beta1 integrin localized at endothelial lateral junctions. J Cell Biol 1998; 141:791 - 804; http://dx.doi.org/10.1083/jcb.141.3.791; PMID: 9566977
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309:623 - 6; http://dx.doi.org/10.1126/science.1114016; PMID: 15947137
   PubMed Web of Science ®Google Scholar
• Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008; 48:1761 - 8; http://dx.doi.org/10.1002/hep.22547; PMID: 19030166
   PubMed Web of Science ®Google Scholar
• Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197:633 - 42; http://dx.doi.org/10.1084/jem.20021756; PMID: 12615904
   PubMed Web of Science ®Google Scholar
• Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791 - 6; http://dx.doi.org/10.1038/nm1268; PMID: 15951748
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93:2645 - 68; http://dx.doi.org/10.1002/jps.20178; PMID: 15389672
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11:81 - 8; http://dx.doi.org/10.1016/S1359-6446(05)03638-X; PMID: 16478695
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10:1093 - 5; http://dx.doi.org/10.1023/A:1018943613122; PMID: 8378254
   PubMed Web of Science ®Google Scholar
• Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, et al. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 2011; 50:131 - 42; http://dx.doi.org/10.2165/11537430-000000000-00000; PMID: 21241072
   PubMed Web of Science ®Google Scholar
• Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28:507 - 32; http://dx.doi.org/10.1023/A:1014414520282; PMID: 11999290
   PubMed Web of Science ®Google Scholar
• Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007; 8:33 - 45; http://dx.doi.org/10.2174/138920007779315053; PMID: 17266522
   PubMed Web of Science ®Google Scholar
• Grimm HP. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn 2009; 36:407 - 20; http://dx.doi.org/10.1007/s10928-009-9129-5; PMID: 19728050
   PubMed Web of Science ®Google Scholar
• Ziegler S, Kronenberger B, Albrecht BA, Kaul A, Gamer AL, Klein CD, et al. Development and evaluation of a FACS-based medium-throughput assay for HCV entry inhibitors. J Biomol Screen 2009; 14:620 - 6; http://dx.doi.org/10.1177/1087057109337161; PMID: 19531666
   PubMed Web of Science ®Google Scholar
• Bumbaca D, Boswell CA, Fielder PJ, Khawli LA. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 2012; 14:554 - 8; http://dx.doi.org/10.1208/s12248-012-9369-y; PMID: 22610647
   PubMed Web of Science ®Google Scholar
• Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 2010; 12:33 - 43; http://dx.doi.org/10.1208/s12248-009-9157-5; PMID: 19924542
   PubMed Web of Science ®Google Scholar
• Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?. Expert Opin Drug Metab Toxicol 2012; 8:141 - 60; http://dx.doi.org/10.1517/17425255.2012.643868; PMID: 22248267
   PubMed Web of Science ®Google Scholar
• Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 2006; 23:95 - 103; http://dx.doi.org/10.1007/s11095-005-8814-3; PMID: 16308668
   PubMed Web of Science ®Google Scholar
• Weinstein JN, van Osdol W. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int J Immunopharmacol 1992; 14:457 - 63; http://dx.doi.org/10.1016/0192-0561(92)90176-L; PMID: 1618598
   PubMed Web of Science ®Google Scholar
• Saito M, Yoshigae Y, Nakayama J, Ogawa Y, Ohtsuki M, Kurihara A, et al. Tissue distribution of humanized anti-human Fas monoclonal antibody (R-125224) based on fas antigen-antibody reaction in collagen-induced arthritis monkeys. Life Sci 2007; 80:2005 - 14; http://dx.doi.org/10.1016/j.lfs.2007.02.043; PMID: 17477938
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495 - 7; http://dx.doi.org/10.1038/256495a0; PMID: 1172191
   PubMed Web of Science ®Google Scholar
• Lo BK. Antibody humanization by CDR grafting. Methods Mol Biol 2004; 248:135 - 59; PMID: 14970494
   PubMedGoogle Scholar
• Lefranc MP. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res 2003; 31:307 - 10; http://dx.doi.org/10.1093/nar/gkg085; PMID: 12520009
   PubMed Web of Science ®Google Scholar
• Stubenrauch K, Wessels U, Regula JT, Kettenberger H, Schleypen J, Kohnert U. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab Dispos 2010; 38:84 - 91; http://dx.doi.org/10.1124/dmd.109.029751; PMID: 19850673
   PubMed Web of Science ®Google Scholar